248 related articles for article (PubMed ID: 16203794)
1. Differential metastasis inhibition by clinically relevant levels of heparins--correlation with selectin inhibition, not antithrombotic activity.
Stevenson JL; Choi SH; Varki A
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):7003-11. PubMed ID: 16203794
[TBL] [Abstract][Full Text] [Related]
2. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents.
Koenig A; Norgard-Sumnicht K; Linhardt R; Varki A
J Clin Invest; 1998 Feb; 101(4):877-89. PubMed ID: 9466983
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory effect of non-anticoagulant heparin (S-NACH) on pancreatic cancer cell adhesion and metastasis in human umbilical cord vessel segment and in mouse model.
Sudha T; Phillips P; Kanaan C; Linhardt RJ; Borsig L; Mousa SA
Clin Exp Metastasis; 2012 Jun; 29(5):431-9. PubMed ID: 22415710
[TBL] [Abstract][Full Text] [Related]
4. Heparin attenuates metastasis mainly due to inhibition of P- and L-selectin, but non-anticoagulant heparins can have additional effects.
Stevenson JL; Varki A; Borsig L
Thromb Res; 2007; 120 Suppl 2():S107-11. PubMed ID: 18023703
[TBL] [Abstract][Full Text] [Related]
5. Binding between heparin and the integrin VLA-4.
Schlesinger M; Simonis D; Schmitz P; Fritzsche J; Bendas G
Thromb Haemost; 2009 Nov; 102(5):816-22. PubMed ID: 19888514
[TBL] [Abstract][Full Text] [Related]
6. An update on heparins at the beginning of the new millennium.
Fareed J; Hoppensteadt DA; Bick RL
Semin Thromb Hemost; 2000; 26 Suppl 1():5-21. PubMed ID: 11011802
[TBL] [Abstract][Full Text] [Related]
7. Antimetastatic activities of modified heparins: selectin inhibition by heparin attenuates metastasis.
Borsig L
Semin Thromb Hemost; 2007 Jul; 33(5):540-6. PubMed ID: 17629852
[TBL] [Abstract][Full Text] [Related]
8. The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on bloodborne metastasis in vivo.
Ludwig RJ; Alban S; Bistrian R; Boehncke WH; Kaufmann R; Henschler R; Gille J
Thromb Haemost; 2006 Mar; 95(3):535-40. PubMed ID: 16525583
[TBL] [Abstract][Full Text] [Related]
9. The inhibition of the integrin VLA-4 in MV3 melanoma cell binding by non-anticoagulant heparin derivatives.
Schlesinger M; Schmitz P; Zeisig R; Naggi A; Torri G; Casu B; Bendas G
Thromb Res; 2012 May; 129(5):603-10. PubMed ID: 22099706
[TBL] [Abstract][Full Text] [Related]
10. The role of VLA-4 binding for experimental melanoma metastasis and its inhibition by heparin.
Schlesinger M; Roblek M; Ortmann K; Naggi A; Torri G; Borsig L; Bendas G
Thromb Res; 2014 May; 133(5):855-62. PubMed ID: 24636486
[TBL] [Abstract][Full Text] [Related]
11. Heparin, low-molecular-weight heparins, and heparin pentasaccharide: basic and clinical differentiation.
Hoppensteadt D; Walenga JM; Fareed J; Bick RL
Hematol Oncol Clin North Am; 2003 Feb; 17(1):313-41. PubMed ID: 12627673
[TBL] [Abstract][Full Text] [Related]
12. Molecular weight determines the frequency of delayed type hypersensitivity reactions to heparin and synthetic oligosaccharides.
Ludwig RJ; Schindewolf M; Alban S; Kaufmann R; Lindhoff-Last E; Boehncke WH
Thromb Haemost; 2005 Dec; 94(6):1265-9. PubMed ID: 16411404
[TBL] [Abstract][Full Text] [Related]
13. Affinity and kinetics of different heparins binding to P- and L-selectin.
Simonis D; Christ K; Alban S; Bendas G
Semin Thromb Hemost; 2007 Jul; 33(5):534-9. PubMed ID: 17629851
[TBL] [Abstract][Full Text] [Related]
14. P-selectin- and heparanase-dependent antimetastatic activity of non-anticoagulant heparins.
Hostettler N; Naggi A; Torri G; Ishai-Michaeli R; Casu B; Vlodavsky I; Borsig L
FASEB J; 2007 Nov; 21(13):3562-72. PubMed ID: 17557930
[TBL] [Abstract][Full Text] [Related]
15. Heparin's anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins.
Wang L; Brown JR; Varki A; Esko JD
J Clin Invest; 2002 Jul; 110(1):127-36. PubMed ID: 12093896
[TBL] [Abstract][Full Text] [Related]
16. Accelerating ability of synthetic oligosaccharides on antithrombin inhibition of proteinases of the clotting and fibrinolytic systems. Comparison with heparin and low-molecular-weight heparin.
Olson ST; Swanson R; Raub-Segall E; Bedsted T; Sadri M; Petitou M; Hérault JP; Herbert JM; Björk I
Thromb Haemost; 2004 Nov; 92(5):929-39. PubMed ID: 15543318
[TBL] [Abstract][Full Text] [Related]
17. Molecular and pharmacologic profile of tinzaparin and a comparable low-molecular-weight bacterial sulfaminoheparosan.
Maddineni J; Ma Q; Hoppensteadt DA; Demir M; Manoni M; Cornelli U; Fareed J
Clin Appl Thromb Hemost; 2004 Jan; 10(1):27-37. PubMed ID: 14979402
[TBL] [Abstract][Full Text] [Related]
18. Chemical synthesis and pharmacological properties of heparin pentasaccharide analogues.
Zhou Z; Zhang L; Wu X; Luo L; Wu J; Xu D; Wu M
Eur J Med Chem; 2022 Apr; 234():114256. PubMed ID: 35279609
[TBL] [Abstract][Full Text] [Related]
19. Modulatory effects of Escherichia coli capsular-derived sulfaminoheparosans and heparins on tissue factor-mediated activation of platelets: flow cytometric analysis.
Maddineni J; Jeske WP; Baltasar F; Cornelli U; Manoni M; Hoppensteadt DA; Fareed J
Clin Appl Thromb Hemost; 2006 Jul; 12(3):311-7. PubMed ID: 16959684
[TBL] [Abstract][Full Text] [Related]
20. Selectin blocking activity of a fucosylated chondroitin sulfate glycosaminoglycan from sea cucumber. Effect on tumor metastasis and neutrophil recruitment.
Borsig L; Wang L; Cavalcante MC; Cardilo-Reis L; Ferreira PL; Mourão PA; Esko JD; Pavão MS
J Biol Chem; 2007 May; 282(20):14984-91. PubMed ID: 17371880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]